WASHINGTON — The Trump administration proposed two Medicare pilot programs to reduce prices for branded drugs bought at pharmacy counters and administered in doctor offices.
If the administration moves forward, the programs could slash Medicare spending on prescription drugs by billions of dollars and cut out-of-pocket costs for beneficiaries.
The pilots, called demonstrations, are part of President Trump’s effort to get drugmakers to lower prices in the United States to levels charged in other rich countries, a policy generally referred to as most-favored nation. The president has signed individual voluntary agreements with 14 companies, and counting, to lower drug prices. Those agreements have focused on Medicaid.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
